Ad-hoc | 23 October 2008 12:04
STRATEC Biomedical Systems AG / Quarter Results/Preliminary Results Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- STRATEC presents preliminary figures for the first nine months of 2008 Birkenfeld, October 23, 2008 The Board of Management of STRATEC Biomedical Systems AG, which is listed in the Prime Standard, hereby announces the preliminary unaudited consolidated figures of the STRATEC Group for the first nine months of the 2008 financial year pursuant to IFRS (International Financial Reporting Standards) and in accordance with Section 15 of the German Securities Trading Act (WpHG).Key Figures (EUR 000s) 01.01.- 09.30.2008 01.01.- 09.30.2007 Change Sales 44,255 50,526 -12.4% Gross performance 48,595 52,239 -7.0% EBITDA 8,964 11,616 -22.8% EBIT 7,240 9,970 -27.4% EBT 7,530 10,058 -25.1% Consolidated net income 5,702 7,011 -18.7% Earnings per share (EUR) 0.50 0.62 -19.4%Including temporary employees, the STRATEC Group had a total of 274 employees as of September 30, 2008 (previous year: 269). The third quarter of the previous year benefited from a positive one-off item in the form of a non-operating special payment contributing Euro 0.8 million to EBIT. Adjusted for this one-off item, consolidated net income fell by 12.4%, and thus in line with the sales performance, in the first nine months of 2008. --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: STRATEC’s business performance met expectations in the third quarter of 2008. For the fourth quarter of 2008 our customers have already placed their orders. The postponement of an order 2008 expected from one customer for the fourth quarter was disclosed in the ad-hoc announcement published on September 30, 2008. Apart from this, all other customers have confirmed, and in some cases increased, their previously communicated purchase forecasts. We therefore do not expect to see any further postponements or cancellations in the collection of analyzer systems in the fourth quarter of 2008. The long-term growth in our company is based on a large number of development and supply contracts already agreed. The development status of existing cooperation projects, as well as new customer orders currently being initiated, give grounds to expect an ongoing positive business performance. In view of its positive cash flow and high volume of liquidity, STRATEC is able to safeguard the planned growth of the company on a long-term basis. Current purchase forecasts of our customers, coupled with the pending market launch of systems currently in the final stages of the development pipeline, mean that there is substantial growth potential from 2009 onwards. STRATEC therefore expects to be able to achieve its previously published average annual growth rates (CAGR 2009 - 2011) of more than 11% for sales and more than 18% for earnings before taxes (EBT). In particular, considerably stronger growth is now expected for 2009 given this reduction in the estimates for 2008. The extensive 'Interim report as of September 30, 2008' will be available for downloading from our internet site from around 3 p.m. (CET) on November 18, 2008. About STRATEC STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange. The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in Germany, the USA, the UK, Switzerland and Romania. Further information can be obtained from: STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestr. 37, 75217 Birkenfeld Germany Phone: +49 7082 7916 190 Fax: +49 7082 7916 999 Email: ir@stratec-biomedical.de 23.10.2008 Financial News transmitted by DGAP ---------------------------------------------------------------------- Language: English Issuer: STRATEC Biomedical Systems AG Gewerbestraße 37 75217 Birkenfeld Deutschland Phone: +49 (0)7082 7916 0 Fax: +49 (0)7082 7916 999 E-mail: info@stratec-biomedical.de Internet: www.stratec-biomedical.de ISIN: DE0007289001 WKN: 728900 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Stuttgart, München, Düsseldorf End of News DGAP News-Service ---------------------------------------------------------------------------